RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$170.44MFY2025, +32.0% a year since FY2013